Two prospective, randomized studies evaluated everolimus 1.5 vs. 3 mg/day with steroids and lowexposure cyclosporine (CsA) (C 2 monitoring) in de novo renal transplant patients. Everolimus dosing was adjusted to maintain a minimum trough level of 3 ng/mL. Study 1 (A2306; n = = 237) had no induction therapy; in Study 2 (A2307; n = = 256) basiliximab was administered (Days 0 and 4). The primary endpoint was renal function at 6 months. CsA C 2 target levels, initially 1200 ng/mL in Study 1 and 600 ng/mL in Study 2, were tapered over time post-transplant. Median creatinine levels in Study 1 were 133 and 132 lmol/L at 6 months in the 1.5 and 3 mg/day groups, respectively, and 130 lmol/L in both groups in Study 2. Biopsyproven acute rejection (BPAR) occurred in 25.0% and 15.2% of patients in the 1.5 and 3 mg/day groups in Study 1, and 13.7% and 15.1% in Study 2. Incidence of BPAR was significantly higher in patients with an everolimus trough < < 3 ng/mL. There were no significant between-group differences in the composite endpoint of BPAR, graft loss or death, nor any significant between-group differences in adverse events in either study. Concentration-controlled everolimus with lowexposure CsA provided effective protection against rejection with good renal function.
Introduction
With 1-year renal graft survival rates now exceeding 90% (1), the new clinical challenge is to develop immunosuppressive regimens that minimize the risk of long-term graft loss while preserving current low rates of acute rejection. Renal function is thought to be a predictor of long-term renal allograft survival (2) , and the introduction of new immunosuppressive drugs offers the opportunity to assess regimens that may reduce renal toxicity without impairing efficacy. In view of the known nephrotoxic potential of calcineurin inhibitors (CNIs), CNI-sparing regimens are an attractive option. Proliferation signal inhibitors are potent immunosuppressants that appear to be non-nephrotoxic (3) , suggesting that use of a proliferation signal inhibitor with a CNI may permit CNI dose reduction without loss of immunosuppressive potency or increased renal toxicity, and thus provide a valuable therapeutic option.
The novel immunosuppressant everolimus (Certican ® , RAD, Novartis Pharma AG, Basel, Switzerland) inhibits the T-lymphocyte proliferative response to cytokine signals (4), thus complementing the inhibitory effect of cyclosporine (CsA) on T-cell-dependent growth factors such as interleukin (IL)-2 (5, 6) . In vitro and preclinical evidence has demonstrated that everolimus enhances the immunosuppressive action of CsA-based regimens (7) (8) (9) (10) , and Phase III trials in which everolimus was used in combination with full-dose CsA have shown equivalent efficacy to mycophenolate mofetil (MMF) (11, 12 ).
An open-label pilot study conducted in 111 de novo renal transplant patients receiving everolimus compared outcomes using full-dose or low-dose CsA (13) . In patients receiving low-dose CsA, the incidence of biopsy-proven acute rejection (BPAR) at 12 months was 7%. Importantly, serum creatinine levels were consistently lower than in the full-dose CsA group, suggesting that use of a proliferation signal inhibitor with low-dose CsA may be an effective immunosuppressive strategy.
In the light of the findings from this pilot study, two prospective, multicenter, randomized studies were set up to evaluate the efficacy and safety of two doses of everolimus (1.5 mg/day vs. 3 mg/day) in combination with low-exposure CsA and corticosteroids in de novo renal transplant recipients. Given the equivalent efficacy demonstrated vs. MMF in Phase III trials, no comparator arm was included. An open-label design was adopted as therapeutic drug monitoring required investigators to adjust the dose of everolimus.
The two studies were undertaken concurrently, with similar protocols other than variations in CsA exposure levels and use of an IL-2 receptor antagonist in one of the trials. The methodologies and results of the two trials, A2306 (Study 1) and A2307 (Study 2) are presented here alongside one another.
Materials and Methods

Study design
Two prospective, parallel-group, open-label studies were undertaken to compare the safety and efficacy of two doses of everolimus used in combination with optimized CsA administration and corticosteroids. The designs were based on previous trials of everolimus in combination with CsA (11) (12) (13) . In Study 1 [based on two Phase III studies with full-dose CsA comparing everolimus with MMF (11, 12) ], no induction therapy was employed. In Study 2 [based on a pilot Phase II study with everolimus in combination with an IL-2 receptor antagonist comparing full-and reduced-dose CsA (13)], the IL-2 receptor antagonist, basiliximab, was administered and CsA exposure targets were, accordingly, lower than in Study 1 (see 'Immunosuppression' below). In all other respects the two studies followed similar protocols. Local medical ethics committees approved the protocols and the studies were performed in accordance with the Declaration of Helsinki and US Food and Drug Administration guidelines for good clinical practice.
Inclusion and exclusion criteria
Adult male or nonpregnant female patients undergoing primary cadaveric, living-unrelated or human leukocyte antigen-mismatched living-related donor kidney transplantation were enrolled and received treatment for up to 1 year. In Study 1, but not in Study 2, patients had to have a functional graft within 24 h. All patients gave written informed consent.
Immunosuppression
Patients were randomized to either 1.5 mg/day or 3 mg/day everolimus, and treatment with all agents was initiated, within 24 h of transplantation. All nonblack patients were randomized to receive 1.5 or 3 mg/day everolimus. As black patients have a higher everolimus clearance rate than Caucasian patients (14) , all black subjects received 3 mg/day everolimus to minimize the risk of graft loss. Everolimus was administered twice daily at 12-hourly intervals, simultaneously with CsA, at either 0.75 mg b.i.d. or 1.5 mg b.i.d. Everolimus trough concentrations were measured on Days 5, 7, 14 and 28 and at Months 2, 3, 4 and 6. A minimum target trough level of 3 ng/mL was adopted based on the results of a previous exposure-response analysis (15) . Dose was adjusted by 0.5 mg or 0.75 mg b.i.d. if trough concentration was less than 3 ng/mL, and trough concentration was measured 5 days after dose adjustment to ensure the target was achieved. The dose was reduced if patients could not tolerate full-dose everolimus and discontinued if necessary.
CsA (Neoral ® , Novartis Pharma AG, Basel, Switzerland) was given twice daily in equal divided doses at 12-h intervals, at an initial dose of 8 mg/kg/day in Study 1 and 4 mg/kg/day in Study 2. Adjustment of CsA dose to target levels, optimized on the basis of pharmacokinetic and pharmacodynamic, efficacy and safety data from previous studies (11) (12) (13) , was achieved through monitoring of CsA concentration 2 h after dosing (C 2 ). C 2 is a superior marker of CsA exposure and hence predictor of acute rejection than trough concentration (16) (17) (18) . Blood CsA (C 2 ) was measured in whole blood taken 2 h (±10 min) after the morning dose on Days 3, 5, 7, 14 and 28 and at Months 2, 3, 4 and 6. CsA dose was adjusted from Day 3 to target C 2 ranges that were tapered over time post-transplant. In Study 1, target C 2 was 1200 ng/mL (range 1000-1400 ng/mL) for Weeks 0-4; 800 ng/mL (range 700-900 ng/mL) for Weeks 5-8; 600 ng/mL (range 550-650 ng/mL) for Weeks 9-12; and 400 ng/mL (range 350-450 ng/mL) for Months 4-12. In Study 2, in which patients also received basiliximab, target C 2 was set lower: 600 ng/mL (500-700 ng/mL) for Weeks 0-8 and 400 ng/mL (range 350-450 ng/mL) from Week 9 to Month 12. CsA exposure could be reduced in the presence of delayed graft function, if patients received antibodies for steroid-resistant rejection episodes or vascular rejection, or for druginduced kidney dysfunction. To provide additional information, CsA trough concentrations were measured in samples taken immediately before the morning dose on Days 5,7,14 and 28, and at study visits for Months 2, 3, 4 and 6; these values were not used to adjust CsA dose.
Intravenous corticosteroid was given according to local practice. Oral prednisone was initiated on Day 1 at a minimum dose of 20 mg/day and continued for at least 12 months. The dose was reduced according to local practice to a minimum of 5 mg/day. In Study 2, basiliximab was given according to the standard dose regimen, 20 mg on Day 0 (within 2 h before transplantation) and Day 4 as an i.v. bolus.
Primary endpoint
The primary endpoint was renal function, measured by calculated glomerular filtration rate (GFR) (Nankivell formula) (19) and calculated creatinine clearance (Cockroft-Gault) (20) or serum creatinine at 6 months.
Secondary endpoints
Efficacy endpoints included the incidence of efficacy failure (first occurrence of either BPAR, graft loss, death or lost to follow-up), graft loss, death and BPAR. All suspected acute rejection episodes were recorded. A graft core biopsy performed within 48 h of suspected rejection was graded according to the 1997 Banff criteria (21) .
All adverse events, infections and serious adverse events were recorded. Laboratory values were determined on Days 7, 14 and 28 and Months 2, 3, 4 and 6 and all data assessed in a central laboratory.
Statistical methods
Data were analyzed separately for each study. All summary statistics are presented by treatment group. All statistical tests were two-sided and used the 0.05 level of significance. Safety and tolerability analyses were performed on the safety populations in each study, defined as all patients who received at least one dose of study medication and underwent at least one safety assessment. Safety evaluations were made to Day 225.
Renal function data to Month 6 were analysed using all data, including those observed after discontinuation of study medication [intent-to-treat (ITT) analysis], and were compared between treatment groups using a two-sided Wilcoxon rank-sum test. Patients with graft loss were excluded from the renal function analyses from the day on which the graft was lost.
Efficacy analyses were conducted on the ITT population using all efficacy data to Day 194. Patients were considered lost to follow-up if they had not experienced BPAR, graft loss or death and their last contact was on Day 154 
Results
This paper reports separately the 6-month results from the two 12-month studies.
Patient populations
All patients were included in the ITT and safety populations. Baseline demographics and background characteristics are shown in Table 1 . There were no significant differences between the 1.5 and 3 mg/day treatment groups in either study, other than the inclusion of all black patients in the 3 mg/day everolimus cohorts (see Materials and Methods). Despite a functioning graft being an inclusion criterion in Study 1, 14% and 17% of patients in each treatment arm had delayed graft function.
Immunosuppression
Overall mean average daily doses of everolimus, including days without medication, were 1.8 and 2.6 mg in Study 1, and 2.2 and 3.0 mg in Study 2, in the 1.5 and 3 mg/day treatment groups, respectively ( Table 2 ). The incidence of everolimus trough levels <3 ng/mL was significantly higher in the 1.5 mg/day group than the 3 mg/day group in both studies at Day 7 (Study 1: 21% vs. 2%, p < 0.001; Study 2: 42% vs. 9%, p < 0.001) and at Day 14 (Study 1: 23% vs. 6%, p < 0.001; Study 2: 34% vs. 15%, p = = 0.001). At Month 6, few patients in either the 1.5 or 3 mg/day groups had trough concentrations of less than 3 ng/mL (Study 1: 3% and 2%; Study 2: 2% and 4%, respectively).
Overall mean average daily CsA dose was similar between the everolimus 1.5 and 3 mg/day treatment groups within each study (Study 1: 3.7 mg/kg vs. 3.4 mg/kg; Study 2: 2.5 mg/kg in both arms). Mean C 2 decreased over time, but were slightly above target after Week 4 in Study 1, remaining above target to Month 6. In Study 2, mean C 2 values slightly exceeded target range at all time points (Table 3) . The overall mean daily dose of corticosteroids was the same in both treatment groups in each study (0.4 mg/kg). In Study 2, all patients received their first dose of basiliximab, and only four patients did not receive their second dose (two in each group).
Renal function
Renal function was good at Month 6 in patients receiving either everolimus 1.5 or 3 mg/day in both studies, as measured by calculated GFR or serum creatinine (Table 4 ). In 2.6 ± 0.7 7.6 ± 4.4 2.2 ± 0.9 5.3 ± 2.0 3.0 ± 0.9 6.6 ± 3.2 (n = 106) (n = 102) (n = 119) (n = 113) (n = 112) (n = 109) (n = 133) (n = 128) Month 3
1.8 ± 0.6 5.4 ± 2.8 2.5 ± 0.7 7.5 ± 3.5 2.4 ± 1.0 6.3 ± 2.5 3.0 ± 1.1 7.9 ± 3.6 (n = 96) (n = 91) (n = 107) (n = 103) (n = 105) (n = 97) (n = 125) (n = 119) Month 6
1.8 ± 0.6 5.2 ± 1.8 2.5 ± 0.7 7.3 ± 3.0 2.4 ± 0.9 6.5 ± 3.8 3.0 ± 0.9 7.6 ± 3.2 (n = 86) (n = 82) (n = 103) (n = 98) (n = 99) (n = 97) (n = 118) (n = 118) Study 1, median calculated GFR values were 65 mL/min and 62 mL/min in the 1.5 and 3 mg/day groups, respectively (median serum creatinine 133 and 132 lmol/L); in Study 2 these values were 66 mL/min and 67 mL/min in (median serum creatinine 130 lmol/L in both treatment groups).
Serum creatinine concentration in Study 1 was ≤132 lmol/L (1.5 mg/dL) at Month 6 in 49% and 50% of patients in the 1.5 and 3 mg/day treatment groups, respectively, and in 53% and 58% of those in Study 2. Serum creatinine was ≤185 lmol/L (2.1 mg/dL) at Month 6 in 88% and 85% of patients in the 1.5 and 3 mg/day treatment groups in Study 1, respectively, and in 89% and 87% of patients in Study 2 ( Table 4) .
Efficacy
The incidence of death or graft loss was low in all patient groups (Table 5 ). Seven patients in Study 1 lost their graft due to acute rejection (n = 2), chronic rejection (n = 1), infection (n = 1), infarcted kidney (n = 1), renal artery thrombosis (n = 1) or other reasons (n = 1). In Study 2, nine grafts were lost; causes included urologic complications, acute rejection, infarcted kidney, malignancy in the allograft, primary nonfunction, technical failure and other reasons (sepsis and micotic aneurysm).
There were no significant differences in either study between the everolimus 1.5 and 3 mg/day groups for any efficacy parameter (Table 5) , although there was a nonsignificant trend to reduced incidence of BPAR in Study 1 among patients in the 3 mg/day cohort compared with the 1.5 mg/day group (p = 0.073). Most cases of BPAR were mild or moderate in severity; only four cases of BPAR were Grade III in Study 1 (two in each treatment group) and two cases in Study 2 (both in the 3 mg/day group). In the 3 mg/day groups the proportion of patients experiencing BPAR was similar in the two studies, as was the proportion of patients in whom the first episode of BPAR occurred by day 14 post-transplant. In the 1.5 mg/day groups, more patients experienced BPAR in Study 1 than Study 2 (n = 100) (n = 97) (n = 121) (n = 119) (n = 116) Month 6 2.0 ± 0.8 447.6 ± 159.6 63.7 ± 31.6 1.9 ± 0.7 459.6 ± 207.9 67.7 ± 58.9 (n = 99) (n = 96) (n = 96) (n = 118) (n = 117) (n = 115) (n = 105) (n = 112) (n = 113) (n = 127)
Number of patients 51 (49%) 56 (50%) 60 (53%) 74 (58%) with serum creatinine (n = 105) (n = 112) (n = 113) (n = 127) ≤132 lmol/L at 6 months (%) Number of patients 92 (88%) 95 (85%) 101 (89%) 111 (87%) with serum creatinine (n = 105) (n = 112) (n = 113) (n = 127) ≤185 lmol/L at 6 months (%) a Calculated by the Nankivell formula (19). ( Table 5) , and a higher proportion of patients with BPAR in Study 1 experienced their first episode within the first 14 days post-transplant (10/34, 29.4%) compared with Study 2 (2/17, 11.8%).
Effect of drug exposure
In both studies, BPAR was more common among patients with a mean everolimus trough concentration below 3 ng/mL compared with those with a trough concentration of 3 ng/mL or above (Figure 1) Figure 1) .
Discontinuations
At the 6-month analysis in Study 1, the incidence of discontinuation of study medication was higher in the 1.5 mg group compared with the 3 mg group. In Study 2, the incidence was similar in both groups. The most common reason for discontinuation of study medication in both studies was adverse events ( Table 6 ). The only adverse event leading to discontinuation of study medication reported by greater than two patients was arthralgia in the Study 1 1.5 mg group. One patient in the 1.5 mg group in both studies discontinued due to thrombocytopenia, and 1 patient in the 3 mg group of Study 2 discontinued due to hyperlipidemia.
Safety
Almost all patients experienced adverse events (Table 7) , with no significant between-group differences relating to the incidence or type of adverse events reported in either study. Infection was common, occurring in 50-60% of patients, with urinary tract infections being the most frequently reported, and with a low incidence of cytomegalovirus infection. The most frequent hematologic adverse event was anemia, with low incidences of leukopenia and thrombocytopenia. Neutropenia occurred in one patient receiving 1.5 mg/day in each study, and in three and two patients in the 3 mg/day group in Studies 1 and 2, respectively. At 6 months, in Study 1, values for mean hemoglobin, white blood cells (WBC), and platelets were 8.3 mmol/L, 8.0 × 10 9 /L, and 244 × 10 9 /L, respectively, in the 1.5 mg/day group and 8.1 mmol/L, 7.4 × 10 9 /L, and 228 × 10 9 /L in the 3 mg/day group. The corresponding values in Study 2 were 7.9 mmol/L, 7.4 × 10 9 /L, and 240 × 10 9 /L in the 1.5 mg/day group and 7.8 mmol/L, 7.0 × 10 9 /L, and 246 × 10 9 /L in the 3 mg/day group. The incidence of new-onset diabetes after transplantation was 4% in the 1.5 mg/day group and 5% in the 3 mg/day group in Study 1, and 4% and 3%, respectively, in Study 2.
The incidence of major adverse cardiac events was low in both studies (3% in both cohorts in Study 1, 2% in both groups in Study 2). Hemolytic uremic syndrome was reported in three patients receiving 1.5 mg/day everolimus and one receiving 3 mg/day in each study.
In Study 1, mean total cholesterol concentration increased from 4.2 and 3.9 mmol/L at baseline to 6.6 and 6.5 mmol/L at Month 6 for the 1.5 mg/day and 3 mg/day cohorts, respectively. For patients in Study 2, the baseline value was 4.3 mmol/L in both cohorts, rising to 6.2 mmol/L and 6.1 mmol/L for the 1.5 and 3 mg/day groups, respectively. The pattern of increase in triglyceride levels was similar. Generally, increases in either total cholesterol or triglycerides were apparent by Month 2-3, after which they stabilized. Lipid-lowering agents, mostly statins, were used in 58.9% and 66.4% of patients in Study 1, and in 66.7% and 72.7% of patients in Study 2 receiving 1.5 or 3 mg/day, respectively.
Discussion
Previous strategies to exploit the synergistic effect of proliferation signal inhibitors and CsA have resulted in an imbalance between immunosuppressive efficacy and renal safety. Early trials, in which fixed-dose sirolimus was used in combination with full-dose CsA, reported low incidences of acute rejection but at the cost of impaired renal function (22) (23) (24) , a finding that resulted from potentiation of CsA nephrotoxicity by sirolimus (25) . Subsequently, early withdrawal of CsA with a maintenance regimen of sirolimus and steroids has been attempted, resulting in improved renal function but with a significantly higher risk of late acute rejection (26) , which is known to be a predictor of chronic rejection (27) and graft loss (28) . Moreover, the relatively high dose of sirolimus necessitated by CsA withdrawal led to an increase in sirolimus-related adverse events (26) . Although everolimus does not increase CsA levels, similar renal findings were found using everolimus with full-dose CsA in Phase III trials (11, 12, 29) .
In the two studies described here, C 2 adjusted dosing of CsA levels was used to achieve exposure lower than those in earlier studies of everolimus and full-dose CsA (11, 12) . After Month 1, the CsA C 2 level in Study 1 was approximately a third lower than typically targeted (30) , and corresponding trough CsA levels were approximately half those seen in studies of everolimus with full-dose CsA (11, 12) . In Study 2, target C 2 levels were approximately half that typically used (30) ; trough levels were a little over a third of those reported in patients receiving everolimus with full-dose CsA (11, 12) . Low CNI exposure may be associated with long-term clinical benefits, such as reduced risk of chronic renal allograft dysfunction (31), hypertension or new-onset diabetes after transplantation (32) , which in turn could contribute to improved patient and graft survival. Concentration-controlled everolimus with low-exposure CsA has the potential to minimize chronic CNI-related toxicity. Further data are required to assess the clinical effect of low-exposure CsA within this regimen over the longer term.
The studies presented here demonstrate that optimizing drug exposure for both everolimus and CsA achieves an effective balance of immunosuppression and renal function. Concentration-controlled everolimus and lowexposure CsA was effective in preventing graft rejection, while the effects on renal function were similar to those reported with current regimens (30, 33, 34) . The optimized everolimus/CsA regimens appeared to be associated with better preservation of renal function than comparable highexposure CsA regimens in Phase II and III everolimus trials (11) (12) (13) . Addition of the IL-2 antagonist basiliximab CMV: cytomegalovirus; NOS: not otherwise specified.
decreased the incidence of acute rejection among those who did not achieve a therapeutic level of everolimus exposure (3 ng/mL).
Hariharan and colleagues (2) have reported that 6-month serum creatinine >132 mmol/L (1.5 mg/dL) is associated with a decline in long-term graft function.
Overall, in the studies reported here, over 50% of patients had a 6-month creatinine value ≤132 mmol/L, indicating excellent long-term graft prognosis. Creatinine values >185 mmol/L (2.1 mg/dL) are associated with less than half the projected graft half-life calculated for those with excellent renal function (2); less then 15% of patients in these studies had values >185 mmol/L.
In terms of efficacy, 6-month rejection rates in Study 1 were similar in the 3 mg/day arm to those seen with higher C 2 levels in combination with MMF or azathioprine and steroids (30) . Overall, the incidence of efficacy failure compares favorably with that previously reported in multicenter efficacy trials. The incidence of rejection was higher with 1.5 mg/day (25%) in Study 1, but only slightly above that reported recently with full-dose tacrolimus-based triple therapy (20%) (33) . When basiliximab was used in addition to everolimus and low-exposure CsA (Study 2), rejection rates were similar to those previously reported with fulldose CsA, MMF, steroids and basiliximab (35) .
A comparison of results in the 1.5 and 3 mg/day cohorts showed no significant differences in efficacy between treatment groups within each trial. Safety differed only by a numerical trend towards increased prevalence of hematologic disturbances in the 3 mg/day groups. There was a higher incidence of rejection in the 1.5 mg/day group in Study 1. Although there was considerable overlap between patients in the different treatment groups in terms of everolimus trough levels, more patients in the 1.5 mg/day group fell below the minimum level of 3 ng/mL, which may account for the higher rate of rejection in this cohort. A minimum everolimus trough level of 3 ng/mL was selected on the basis of a retrospective analysis of data from a Phase III trial of everolimus which showed a strong relationship between an everolimus trough level >3 ng/mL and prevention of acute rejection, regardless of CsA exposure (15) . Results presented here also indicate that an everolimus trough level >3 ng/mL is associated with a reduced risk of rejection. Few acute rejections occurred after month 3. Thus, therapeutic drug monitoring of everolimus can enhance both efficacy and safety of the regimen by allowing initial use of 1.5 mg/day with dose increments as required to ensure a trough concentration of at least 3 ng/mL. Black patients, in whom CsA and everolimus clearance rate is higher than nonblacks (14) , still experienced a rate of acute rejection higher than nonBlacks, suggesting caution must still be observed in monitoring everolimus and CsA levels.
In conclusion, concentration-controlled everolimus in combination with low-exposure CsA results in effective protection against rejection with good renal function. Therapeutic drug monitoring to optimize exposure to both everolimus and CsA offers an innovative strategy that allows individualization of immunosuppression after transplantation. Long-term data are required to determine whether use of this regimen also helps to reduce risk of chronic allograft nephropathy.
